# Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

> **NCT00179608** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 28 (—)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** CC-5013

## Key facts

- **NCT ID:** NCT00179608
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-01
- **Primary completion:** 2007-06-01
- **Final completion:** 2007-06-01
- **Target enrollment:** 28 (—)
- **Last updated:** 2019-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179608, "Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00179608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*